6 April 2021 | 09:26am
StockMarketWire.com - Cancer therapies and diagnostics group Avacta entered into a global distribution agreement with ABCAM to sell the company sSARS-CoV-2 research Affimer reagents.
Under the worldwide, non-exclusive distribution agreement, ABCAM would enable the global research community to access Avacta s SARS-CoV-2 spike protein Affimer research reagents through its on-line catalogue.
At 9:26am: [LON:AVCT] Avacta Group PLC share price was 0p at 111.5p
Story provided by StockMarketWire.com
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Latest share price and company details: